Author

Mohamed Hossam Sobhy

Observed names: Mohamed H. Sobhy, Mohamed Sobhy

Institutions: Heliopolis University, University of Tennessee at Knoxville

Observed institutions: Heliopolis University, University of Tennessee at Knoxville

ORCID: 0000-0002-9007-1157

Observed ORCID: 0000-0002-9007-1157

OpenAlex ID: A5087014400

The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters

2022 · Iart Luca Shytaj, Mohamed Fares, et al. · mBio · 44

In silico molecular docking, dynamics simulation and repurposing of some VEGFR-2 inhibitors based on the SARS-CoV-2-main-protease inhibitor N3

2022 · Sanadelaslam El-Hddad, Mohamed Sobhy, et al. · Journal of Biomolecular Structure and Dynamics · 15

Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation

2024 · Sanadelaslam S. A. El-Hddad, Mohamed H. Sobhy, et al. · RSC Advances · 7

A unique compound ameliorating endoplasmic reticulum stress and insulin resistance by binding to β tubulin

2024 · Keigo Horiuchi, Goshi Matsushima, et al. · The FASEB Journal · 2

Exploring the clinical potential of circulating LncRNAs in breast cancer: insights into primary signaling pathways and therapeutic interventions

2024 · Tohada M. AL-Noshokaty, Rehab Abdelhamid, et al. · Functional & Integrative Genomics

Author response for "Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation"

2024 · Sanadelaslam S. A. El-Hddad, Mohamed H. Sobhy, et al. · Publons reviews and discussion

Works count: 6

Citation count: 68

H-index: 3

I10-index: 2